ArticlePharmacognosy magazine2014
Anti-tumor activity of safranal against neuroblastoma cells.
Article in Pharmacognosy magazine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 58 citations in OpenAlex.
- Berberine nanoemulsion attenuates bisphenol A-induced metabolic impairment through NF-κB signaling in the liver of rat.Toxicology reports · 2025Article
- A Review on the Potential Effects of Curcumin in the Treatment of Neuroblastoma and its Underlying Mechanisms.Current medicinal chemistry · 2025Review
- Protective Effect of Berberine Nanoparticles Against Cardiotoxic Effects of Arsenic Trioxide.Cardiovascular toxicology · 2024Article
- Network pharmacology and experimental verification reveal the mechanism of safranal against glioblastoma (GBM).Frontiers in oncology · 2023Article
- Pharmacological effects of Safranal: An updated review.Iranian journal of basic medical sciences · 2023Review
- Molecular Mechanisms behind Safranal's Toxicity to HepG2 Cells from Dual Omics.Antioxidants (Basel, Switzerland) · 2022Article
- Saffron forMetabolism open · 2021Article
- The role of Safranal and saffron stigma extracts in oxidative stress, diseases and photoaging: A systematic review.Heliyon · 2021Review
- Flavonoids Activation of the Transcription Factor Nrf2 as a Hypothesis Approach for the Prevention and Modulation of SARS-CoV-2 Infection Severity.Antioxidants (Basel, Switzerland) · 2020Article
- Safrana l Prevents Prostate Cancer Recurrence by Blocking the Re-activation of Quiescent Cancer CellsFrontiers in cell and developmental biology · 2020Article
- Bioactivity and Bioavailability of the Major Metabolites ofMolecules (Basel, Switzerland) · 2019Review
- Evaluation of Biological Response of Lettuce (Molecules (Basel, Switzerland) · 2019Article
- Safranal induces DNA double-strand breakage and ER-stress-mediated cell death in hepatocellular carcinoma cells.Scientific reports · 2018Article
- The protective effects of crocin in the management of neurodegenerative diseases: a review.American journal of neurodegenerative disease · 2018Review
- Saffron: An Old Medicinal Plant and a Potential Novel Functional Food.Molecules (Basel, Switzerland) · 2017Review
- The Neuroprotective Effects of Thymoquinone: A Review.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSafranal (2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxaldehyde, C10H14O) is an active ingredient in the saffron, which is used in traditional medicine, and also, the biological activity of saffron in anti-cancer is in development. It has been reported to have anti-oxidant effects, but its anti-tumor effects remain uncertain. The aim of this study was to evaluate effects of safranal on anti-tumor on neuroblastoma cells. MATERIALS AND
methodsNeuroblastoma cells were cultured and exposed to safranal (0, 10, 15, 20, 50 μg/ml). Cell proliferation was examined using the 3-(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay. Apoptotic cells, cell cycle distribution, and sub-G1 fraction were analyzed using flow cytometric analysis after propidium iodide staining.
resultsSafranal inhibited the growth of malignant cells in a dose-and time-dependent manner. The IC (50) values against the neuroblastoma cell line were determined as 11.1 and 23.3 μg/ml after 24 and 48 h, respectively. Safranal induced a sub-G1 peak in the flow cytometry histogram of treated cells compared to control cells indicating that apoptotic cell death is involved in safranal toxicity.
conclusionsOur pre-clinical study demonstrated a neuroblastoma cell line to be highly sensitive to safranal-mediated growth inhibition and apoptotic cell death. Although the molecular mechanisms of safranal action are not yet clearly understood, it appears to have potential as a therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.